By Kosaku Narioka
Takeda Pharmaceutical is scheduled to report its fourth-quarter results on Thursday. Here's what you need to know:
NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That compares with a net loss of Y3.0 billion in the year-earlier period.
REVENUE FORECAST: Fourth-quarter revenue is estimated to have risen 2.3% on year to Y1.076 trillion, the poll shows.
Shares have gained 3.2% so far this year after rising a 3.1% in 2024.
WHAT TO WATCH:
--Takeda is expected to provide fiscal-year guidance, with investors eyeing sales and profit forecasts as well as any comments on potential U.S. tariffs.
--Investors will monitor sales momentum of key drugs. Third-quarter sales of ulcerative colitis drug Entyvio fell 0.8% to Y225.8 billion, while plasma-derived products rose 1.7% to Y248.5 billion.
--Margin trends will also be in focus after operating profit margin declined to 5.9% in the third quarter from 9.4% a year earlier amid global inflation pressures.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
May 07, 2025 07:11 ET (11:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。